Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Curium Completes Monrol Acquisition To Expand Lutetium-177 Capacity
Details : The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
March 28, 2025
Lead Product(s) : Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Monrol and FutureChem Announced a Clinical Supply Partnership
Details : 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 18, 2022
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Sma...
Product Name : Zepzelca
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 22, 2021
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : 177-Lu EBTATE
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Molecular Targeting Technologies
Deal Size : Undisclosed
Deal Type : Agreement
MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.
Details : A timely and sustainable supply of a key therapeutic ingredient (n.c.a.177Lu) needed for the development and launch of company lead asset 177Lu-EBTATE and other EB platform technologies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 24, 2021
Lead Product(s) : 177-Lu EBTATE
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Molecular Targeting Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
